Synaptogenix (NASDAQ:TAOX) Stock Price Down 3.2% – Here’s What Happened

Synaptogenix, Inc. (NASDAQ:TAOX)’s stock price traded down 3.2% during mid-day trading on Wednesday . The company traded as low as $3.49 and last traded at $3.61. 114,507 shares were traded during mid-day trading, a decline of 4% from the average session volume of 118,875 shares. The stock had previously closed at $3.73.

Analyst Upgrades and Downgrades

Several research firms have commented on TAOX. Wall Street Zen upgraded Synaptogenix from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Synaptogenix in a report on Tuesday, April 21st. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Synaptogenix Stock Performance

The company has a market cap of $27.34 million, a P/E ratio of -0.28 and a beta of 1.42. The firm has a 50 day moving average price of $4.50 and a 200-day moving average price of $4.69.

Synaptogenix (NASDAQ:TAOX) last announced its earnings results on Wednesday, May 13th. The company reported $0.43 earnings per share (EPS) for the quarter. The company had revenue of $5.96 million for the quarter.

About Synaptogenix

Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer’s disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University.